Posted on avacta site.....1 Jan 2022 12:10
PrivacyPrivacy
London South East
Share PricesAvacta Share PriceAvacta Share Chat
Pin to quick picksAvacta Share Chat (AVCT)
AVCT Share Price
AVCT Share
Price
AVCT Share News
AVCT Share
News
AVCT Share Chat
AVCT Share
Chat
39
AVCT Share Trades
AVCT Share
Trades
120
AVCT Live RNS
AVCT
Live RNS
AVCT Information Buy AVCT SharesBuy AVCT SharesAdd AVCT to WatchlistAdd AVCT to WatchlistAdd AVCT to AlertAdd AVCT to AlertAdd AVCT to myTerminalAdd AVCT to myTerminal
Share Price Information for Avacta (AVCT)
London Stock Exchange
Share Price:
126.40
Bid:
123.00
Ask:
126.00
Change:
0.40 (0.32%)
Spread: 3.00 (2.44%)Open: 124.50High: 126.40Low: 126.40Prev. Close: 126.40
AVCT Live PriceLast checked at 12:05:42
Share Discussion for Avacta
Regular
Premium
Filters ON
View
Post Message
Open All Threads
25
123
CDC Withdraws Use of PCR Test for COVID and Finally Admits the Test Can Not Differentiate Between th
Started: quercusrobor, 01 Jan 2022 10:41
Last post: craiga24 01 Jan 2022 11:52
Go to Thread
10 replies
The British Government could be facing calls to explain the 'baffling' decision to rely on securing
Started: quercusrobor, 01 Jan 2022 07:54
Last post: RevoltingPeasant 01 Jan 2022 11:45
Go to Thread
14 replies
quercusrobor
Today 07:54
Posts: 929
Price: 126.40
Plans to manufacture lateral flow tests in the UK were shelved amid fears of legal challenges over the Government’s alleged “chumocracy”, it has been claimed.
In the early months of 2021, ministers called a halt to months of work with British companies that had been intended to establish an onshore manufacturing capability for the rapid Covid tests.
The result has left the UK relying on securing Chinese-made kits, with the devices currently unavailable in many parts of the country.
The shortage threatens to prevent people returning to work next week, and to hamper efforts to clamp down on the spread of omicron.
On Friday, figures in the diagnostics industry pointed to a slew of legal actions against Boris Johnson’s Government by the Good Law Project to explain the “baffling” decision not to build manufacturing capability in the UK.
The campaign organisation, which is led by Jolyon Maugham QC, a Remain-supporting barrister, uses judicial review actions in the High Court to challenge government policy and actions it disagrees with.
The group has launched cases opposing government policy on Brexit and, more recently, against procurement decisions in the pandemic response.
The scrutiny has contributed to a criticism of a “chumocracy” against senior ministers, including Matt Han****, who came under fire after a contract was awarded to a business owner who used to run a pub close to the former health secretary’s home.
Mr Han**** has strenuously denied any personal wrongdoing, while ministers more broadly have defended bypassing some civil service procurement red tape in the early stages of the pandemic d